secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001662774-25-000011
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics FY2024 net loss $56.8M; Phase 3 NEAT trial exceeds 50% enrollment
--------------------------------------------------------------------------------

- Net loss of $56.8M ($1.31/share) for FY2024; cash $40.8M provides runway into 2026.
- Phase 3 NEAT trial enrolled 61 participants (>50%); topline results expected Q4 2025.
- Received FDA Fast Track designation (June 2024); Phase 3 ATTeST results published in The Lancet Neurology.
- R&D $18.6M, G&A $17.6M; operating cash burn $31.9M includes $5M milestone and $17.1M goodwill impairment.
- Appointed Dr. William Whitehouse to SAB; USPTO allowed patent claims extending to 2036 for eDSP in A-T.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000166277425000011/0001662774-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000166277425000011/qncx-20250324.htm
  HTML page:      https://secwatch.observer/filing/0001662774-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer